Treatment with activin receptor-like kinase 5 inhibitor (ALK5i) differently affects collagen 1A1 deposition in mouse models of toxic and metabolically induced liver fibrosis

被引：0

作者：

Antolic, M. ^{[1
]}

Majstorovic, O. ^{[1
]}

Milutinovic, V. ^{[1
]}

Ivis, S. Vidovic ^{[1
]}

Ognjenovic, A. ^{[1
]}

Radicevic, A. Paravic ^{[1
]}

Glojnaric, I. ^{[1
]}

Cuzic, S. ^{[1
]}

机构：

[1] Selvita Ltd, Zagreb, Croatia

来源：

VIRCHOWS ARCHIV | 2022年 / 481卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

PS-13-001

引用

页码：S134 / S134

页数：1

共 10 条

[1] Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFP/ALK5 signaling
Goumans, MJ
Valdimarsdottir, G
Itoh, S
Lebrin, F
Larsson, J
Mummery, C
Karlsson, S
ten Dijke, P
MOLECULAR CELL, 2003, 12 (04) : 817 - 828
[2] An Activin Receptor-Like Kinase 5 Inhibitor Reduces Collagen Deposition in a Rat Dermal Incision Wound Healing Model
Bian, Feng
Render, James
Ren, Xiao-Dan
Chio, Christopher
Chan, Kam
Boys, Mark
Lala, Deepak S.
Pocalyko, David
PLASTIC AND RECONSTRUCTIVE SURGERY, 2011, 128 (05) : 451E - 459E
[3] ACTIVIN RECEPTOR-LIKE KINASE ALK5 AND ALK1 ARE BOTH REQUIRED FOR TGFβ-INITIATED CHONDROGENIC DIFFERENTIATION OF MESENCHYMAL STEM CELLS
de Kroon, L. M.
Davidson, E. N. Blaney
Narcisi, R.
van Beuningen, H. M.
van Osch, G. J.
van der Kraan, P. M.
OSTEOARTHRITIS AND CARTILAGE, 2015, 23 : A79 - A79
[4] SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7
Inman, GJ
Nicolás, FJ
Callahan, JF
Harling, JD
Gaster, LM
Reith, AD
Laping, NJ
Hill, CS
MOLECULAR PHARMACOLOGY, 2002, 62 (01) : 65 - 74
[5] Activin Receptor-Like Kinase Receptors ALK5 and ALK1 Are Both Required for TGFβ-Induced Chondrogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells
de Kroon, Laurie M. G.
Narcisi, Roberto
Davidson, Esmeralda N. Blaney
Cleary, Mairead A.
van Beuningen, Henk M.
Koevoet, Wendy J. L. M.
van Osch, Gerjo J. V. M.
van der Kraan, Peter M.
PLOS ONE, 2015, 10 (12):
[6] Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study
Jung, Su Young
Hwang, Sunjin
Clarke, Jeffery M.
Bauer, Todd M.
Keedy, Vicki L.
Lee, Hukeun
Park, Neunggyu
Kim, Seong-Jin
Lee, Jangik, I
INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 812 - 820
[7] Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study
Su Young Jung
Sunjin Hwang
Jeffery M. Clarke
Todd M. Bauer
Vicki L. Keedy
Hukeun Lee
Neunggyu Park
Seong-Jin Kim
Jangik I. Lee
Investigational New Drugs, 2020, 38 : 812 - 820
[8] Transforming growth factor beta 1 increases collagen content, and stimulates procollagen I and tissue inhibitor of metalloproteinase-1 production of dental pulp cells: Role of MEK/ERK and activin receptor-like kinase-5/Smad signaling
Lin, Po-Shuen
Chang, Hsiao-Hua
Yeh, Chien-Yang
Chang, Mei-Chi
Chan, Chiu-Po
Kuo, Han-Yueh
Liu, Hsin-Cheng
Liao, Wan-Chuen
Jeng, Po-Yuan
Yeung, Sin-Yuet
Jeng, Jiiang-Huei
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2017, 116 (05) : 351 - 358
[9] Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer
Choi, Jiwon
Park, Jiyoung
Cho, Ilyoung
Sheen, Yhunyhong
RADIOLOGY AND ONCOLOGY, 2022, 56 (02) : 185 - 197
[10] EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells
Park, Chul-Yong
Kim, Dae-Kee
Sheen, Yhun Yhong
CANCER SCIENCE, 2011, 102 (10) : 1889 - 1896

← 1 →